Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates.
作者信息
Walther Carl P, Winkelmayer Wolfgang C, Navaneethan Sankar D
机构信息
Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
出版信息
J Am Soc Nephrol. 2021 Jun 1;32(6):1319-1321. doi: 10.1681/ASN.2020121724. Epub 2021 Apr 8.
Abstract
摘要
相似文献
1
Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates.慢性肾脏病中肾小球滤过率估算的黑人种族系数与糖尿病药物治疗：全国性评估。
J Am Soc Nephrol. 2021 Jun 1;32(6):1319-1321. doi: 10.1681/ASN.2020121724. Epub 2021 Apr 8.
2
National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race.全国慢性肾脏病患病率估计值及不考虑种族因素估算肾小球滤过率的潜在影响
J Am Soc Nephrol. 2021 Jun 1;32(6):1454-1463. doi: 10.1681/ASN.2020121780. Epub 2021 May 6.
3
Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.有和无心血管疾病史的 2 型糖尿病患者的处方：英国 CPRD 的描述性分析。
Clin Ther. 2021 Feb;43(2):320-335. doi: 10.1016/j.clinthera.2020.12.015. Epub 2021 Feb 10.
4
Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes.美国2型糖尿病成年患者中SGLT2i和GLP1RA的使用 prevalence
J Diabetes Complications. 2022 Jun;36(6):108204. doi: 10.1016/j.jdiacomp.2022.108204. Epub 2022 Apr 30.
5
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂在伴有 2 型糖尿病和轻度/中度慢性肾脏病患者中的疗效比较。
Diabetes Obes Metab. 2024 Apr;26(4):1273-1281. doi: 10.1111/dom.15427. Epub 2024 Jan 8.
6
Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.2020年使用胰岛素治疗控制不佳的2型糖尿病
JAMA. 2020 Jun 16;323(23):2419-2420. doi: 10.1001/jama.2020.1303.
7
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.比较胰高血糖素样肽受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者预防主要不良心血管和肾脏结局的效果。
Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
8
Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial.随机评估远程管理方案以改善指南导向的医学治疗：DRIVE 试验。
Circulation. 2024 Jun 4;149(23):1802-1811. doi: 10.1161/CIRCULATIONAHA.124.069494. Epub 2024 Apr 7.
9
The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.美国食品药品监督管理局二甲双胍标签变更与 CKD 患者二甲双胍处方中的种族和性别差异。
J Am Soc Nephrol. 2020 Aug;31(8):1847-1858. doi: 10.1681/ASN.2019101119. Epub 2020 Jul 13.
10
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.新型基于肌酐和胱抑素 C 的估算肾小球滤过率方程，无需考虑种族因素。
N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23.
引用本文的文献
1
Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes.克服在使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对有和没有2型糖尿病的人群进行心肾保护方面的差异。
J Clin Endocrinol Metab. 2025 Aug 7;110(9):e2852-e2863. doi: 10.1210/clinem/dgaf301.
2
A Working Framework to Address Diversity, Equity, and Inclusion in Undergraduate Medical Education.本科医学教育中解决多样性、公平性和包容性问题的工作框架。
Med Sci Educ. 2024 May 28;34(5):1123-1131. doi: 10.1007/s40670-024-02065-1. eCollection 2024 Oct.
3
Impact of Removing Race Variable on CKD Classification Using the Creatinine-Based 2021 CKD-EPI Equation.使用基于肌酐的2021年慢性肾脏病流行病学协作组（CKD-EPI）方程去除种族变量对慢性肾脏病（CKD）分类的影响
Kidney Med. 2022 Apr 28;4(6):100471. doi: 10.1016/j.xkme.2022.100471. eCollection 2022 Jun.
4
Kidney Function Assessment in African American Patients: A Narrative Review for Pharmacists.非裔美国患者的肾功能评估：药剂师的叙述性综述
Pharmacy (Basel). 2022 Jun 20;10(3):65. doi: 10.3390/pharmacy10030065.
5
Health inequities and the inappropriate use of race in nephrology.健康不公平和肾脏病学中种族的不当使用。
Nat Rev Nephrol. 2022 Feb;18(2):84-94. doi: 10.1038/s41581-021-00501-8. Epub 2021 Nov 8.
本文引用的文献
1
Black Kidney Function Matters: Use or Misuse of Race?黑人肾功能问题：种族的使用还是误用？
JAMA. 2020 Aug 25;324(8):737-738. doi: 10.1001/jama.2020.13378.
2
The FDA Metformin Label Change and Racial and Sex Disparities in Metformin Prescription among Patients with CKD.美国食品药品监督管理局二甲双胍标签变更与 CKD 患者二甲双胍处方中的种族和性别差异。
J Am Soc Nephrol. 2020 Aug;31(8):1847-1858. doi: 10.1681/ASN.2019101119. Epub 2020 Jul 13.
3
Estimation of Glomerular Filtration Rate With vs Without Including Patient Race.不考虑与考虑患者种族的肾小球滤过率估计。
JAMA Intern Med. 2020 May 1;180(5):793-795. doi: 10.1001/jamainternmed.2020.0045.
4
Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.黑人及白人 2 型糖尿病患者慢性肾脏病的发病和进展。
Clin J Am Soc Nephrol. 2018 Jun 7;13(6):884-892. doi: 10.2215/CJN.11871017. Epub 2018 May 24.
Zotero 插件